Core Insights - The article presents a ranking of 33 Hong Kong-listed medical service companies based on their stock price performance as of September 30, 2025, highlighting significant price increases and declines among these companies [1][2]. Group 1: Top Performers - The top performer is Brainstorm Cell Therapeutics (脑动极光-B) with a stock price of HKD 8.58, reflecting a remarkable increase of 166.46% [1]. - MediWound (麦迪卫康) ranks second with a stock price of HKD 1.23, showing a growth of 136.54% [1]. - Yonghe Medical (雍禾医疗) comes in third with a stock price of HKD 2.05, marking a rise of 127.78% [1]. Group 2: Notable Declines - The company with the largest decline is Yimeng Group (云康集团), with a stock price of HKD 1.28, experiencing a drop of 86.15% [1]. - Meizhong Jiahe (美中嘉和) follows with a stock price of HKD 3.20, down by 70.91% [1]. - Another significant decline is seen in Yimeng Sunshine (一昧阳光), which has a stock price of HKD 17.00, down by 76.06% [1]. Group 3: Market Capitalization - Fosun Pharma (复星医药) has the highest market capitalization at HKD 680.48 billion, with a stock price of HKD 25.78 [2]. - Far East Horizon (远东宏信) ranks second with a market cap of HKD 328.32 billion and a stock price of HKD 6.87 [2]. - Global Medical (环球医疗) holds a market cap of HKD 114.82 billion, with a stock price of HKD 6.07 [2].

Group 1 - The core point of the news is that Mialkos Tomasz Jakub increased his stake in Kangsheng Global (09960.HK) by purchasing 262,500 shares at an average price of HKD 1.5325 per share, resulting in a total investment of approximately HKD 402,300 [1][2] - Following this transaction, Mialkos Tomasz Jakub's total shareholding increased to 62,480,500 shares, raising his ownership percentage from 5.97% to 6.00% [1][2]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康聖環球基因技術有限公司 呈交日期: 2025年10月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09960 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | USD | | 0.00025 | USD | | 500,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 2,000,000,000 | USD | | 0.00025 | USD | | 500,000 | 本月底法定/註 ...

Definitions [Definitions](index=3&type=section&id=%E9%87%8A%E4%B9%89) This section provides definitions of key terms used throughout the report Company Information [Board of Directors and Committees](index=6&type=section&id=%E8%91%A3%E4%BA%8B%E4%BC%9A%E5%8F%8A%E5%A7%94%E5%91%98%E4%BC%9A) This section lists the company's Board of Directors (executive, non-executive, independent non-executive directors) and the composition of the Audit, Remuneration, and Nomination Committees - Board members include **Dr. Huang Shiang** (Chairman and CEO), **Mr. Tu Zanbing**, **Ms. Chai Haijie** as executive directors; **Mr. Huang Ruijin**, **Mr. Peng Wei**, **Ms. Huang Lu** as non-executive directors; and **Dr. Yao Shanglong**, **Dr. Xia Xinping**, **Mr. Gu Huaming** as independent non-executive directors[11](index=11&type=chunk) - The Audit Committee Chairman is **Dr. Xia Xinping**, the Remuneration Committee Chairman is **Mr. Gu Huaming**, and the Nomination Committee Chairman is **Dr. Huang Shiang**[11](index=11&type=chunk) [Corporate Administrative Information](index=6&type=section&id=%E5%85%AC%E5%8F%B8%E8%A1%8C%E6%94%BF%E4%BF%A1%E6%81%AF) This section provides key administrative and contact information, including the company secretary, authorized representatives, legal advisors, auditors, registered office, principal place of business, website, share registrar, and principal bankers - The company secretary is **Ms. Chai Haijie** and **Ms. Li Meiyi** (resigned on August 29, 2025), and authorized representatives are **Ms. Chai Haijie** and **Mr. Tu Zanbing** (appointed on August 29, 2025)[11](index=11&type=chunk) - The auditor is **Ernst & Young**, and Hong Kong legal counsel is Jingtian & Gongcheng LLP[11](index=11&type=chunk) - The company's website is www.kindstar.com.cn, and stock code is **9960**[12](index=12&type=chunk) Business Review and Outlook [Specialized Diagnostic Testing Business Remains Robust](index=8&type=section&id=%E4%B8%93%E7%A7%91%E7%89%B9%E6%A3%80%E4%B8%9A%E5%8A%A1%E4%BF%9D%E6%8C%81%E7%A8%B3%E5%81%A5) In H1 2025, the company optimized operations, strengthened its market position in six core specialized diagnostic testing areas like hematology, neurology, and oncology, and expanded its business through technological innovation and strategic M&A - Hematology diagnostic testing services added over **90** new hospital clients, the pediatric hematology segment added **48** new partner hospitals, and NGS Ig/TCR rearrangement technology products sales grew over **50%**[14](index=14&type=chunk) - The neurology field added **34** new diagnostic projects, **44** new partner referral hospitals, and deepened cooperation with Southern Hospital[14](index=14&type=chunk) - In oncology, **15** new key partners were added, including Peking University Cancer Hospital, with solid tumor large panel testing and solid tumor MRD testing growing over **100%** year-on-year[15](index=15&type=chunk) - The acquisition of Kindstar Medical Guangzhou was completed in January 2025, establishing a comprehensive full-disease course diagnostic system covering solid tumor early screening, early diagnosis, recurrence monitoring, and companion diagnostics[15](index=15&type=chunk)[16](index=16&type=chunk) - **UriFind®** (urothelial carcinoma auxiliary diagnostic reagent kit) sales volume increased by approximately **82%** year-on-year in H1 2025[21](index=21&type=chunk) - The maternal and child specialty team was established to promote growth in pediatric endocrinology referral business[17](index=17&type=chunk) - In cardiovascular diagnostic testing, mass spectrometry platform R&D and testing capabilities improved, with **1** new Class I reagent filing for mass spectrometry testing and **1** new Class II in vitro diagnostic kit approved, and **3** clinical mass spectrometry laboratories co-built[17](index=17&type=chunk) [Scientific Research and Innovation Drive Industry Development](index=10&type=section&id=%E7%A7%91%E7%A0%94%E5%88%9B%E6%96%B0%E9%A9%B1%E5%8A%A8%E8%A1%8C%E4%B8%9A%E5%8F%91%E5%B1%95) In H1 2025, the company significantly increased R&D investment, achieving notable innovations including academic publications, numerous patent applications, and new diagnostic projects, particularly in CAR-T monitoring, leukemia MRD monitoring, and AI-integrated pathology diagnostics - In H1 2025, the Group's R&D department published **33** articles, filed **67** patent applications (**29** of which were authorized), and obtained **24** copyrights[18](index=18&type=chunk) - **56** new R&D diagnostic projects were added, covering molecular biology, flow cytometry, cytogenetics, and pathology diagnostic technologies[18](index=18&type=chunk) - Key developments include CAR-T monitoring and evaluation projects, acute myeloid leukemia MRD monitoring (detection limit improved to **0.1%**), fusion gene quantitative detection (NGS technology for **144** genes), and plans to integrate remote scanning and AI analysis to enhance comprehensive diagnostic capabilities[18](index=18&type=chunk) [Immunome Profiling Products Show Significant Potential](index=10&type=section&id=%E5%85%8D%E7%96%AB%E7%BB%84%E5%BA%93%E4%BA%A7%E5%93%81%E6%BD%9C%E5%8A%9B%E5%87%B8%E6%98%BE) The company's core immunome profiling product, 'LymphoTrack,' continues to expand in hematological malignancy MRD detection, showing significant revenue growth and international quality certification, while health monitoring and immune reconstitution products have deepened market collaborations - The core product **LymphoTrack** (used for hematological malignancy minimal residual disease detection) has covered over **160** institutions in **26** provinces, with revenue growing nearly **30%** compared to H1 2024[19](index=19&type=chunk) - Kindstar Biotech's Ig/TCR project achieved a perfect score in the EuroClonality EQA program, becoming the only laboratory in China to participate and pass with a perfect score[19](index=19&type=chunk) - Health monitoring product **Kangbeice** and immune reconstitution and monitoring product **Fantech** continue to deepen cooperation with renowned enterprises, institutions, and pharmaceutical companies[19](index=19&type=chunk) [Specialized Diagnostic Reagents](index=10&type=section&id=%E7%89%B9%E6%A3%80%E8%AF%95%E5%89%82) The company's specialized diagnostic reagent product line continues to expand, covering NGS capture, multiplex amplification, universal library preparation, single gene mutation, fusion gene, and transplantation series, with significant growth in proprietary product sales and progress in acquired IVD businesses, such as a substantial increase in UriFind® sales - Haixi Bio's product line has developed and transferred over **180** products, covering NGS capture-based, NGS multiplex amplification series, NGS universal library preparation series, single gene mutation detection series, fusion gene detection series, and transplantation series products[20](index=20&type=chunk) - The NGS reagent kits produced by Haixi Bio are compatible with an increasing number of sequencing platforms, and its **74** fusion gene screening projects are at a leading domestic level[20](index=20&type=chunk) - In H1 2025, the Group's proprietary specialized diagnostic reagent business sales increased by over **20%** compared to H1 2024[20](index=20&type=chunk) - **UriFind®** (the first domestically approved reagent kit for auxiliary diagnosis of urothelial carcinoma) completed procurement processes with **11** hospitals and **8** third-party clients, with reagent sales volume increasing by approximately **82%** year-on-year in H1 2024[21](index=21&type=chunk) - The blood-based non-invasive gastric cancer early detection product **Gastromia® (Wei Yijian)** has completed in vitro diagnostic reagent registration clinical research and entered the product registration application phase, with a negative accuracy rate of over **99%**[21](index=21&type=chunk) [Research Services and Contract Research Organization (CRO)](index=11&type=section&id=%E7%A7%91%E7%A0%94%E6%9C%8D%E5%8A%A1%E5%8F%8A%E5%90%88%E7%B4%84%E7%A0%94%E7%A9%B6%E7%B5%84%E7%B9%94%EF%BC%88%E3%80%8CCRO%E3%80%8D%EF%BC%89) Leveraging its R&D innovation and bioinformatics expertise, the company has become a multi-omics research service provider for leading domestic and international biological research institutions and pharmaceutical companies, achieving significant growth in research service revenue and actively expanding into overseas markets and new product lines - Since 2023, the company has been a multi-omics research service provider for domestic and international biological research institutions and pharmaceutical companies, operating **3** PacBio Revio platforms, with **2** serving the domestic market and **1** serving the overseas market[22](index=22&type=chunk) - Fully upgraded to the latest PacBio SPRQ reagents, single-cell output increased by up to **49%**, positioning its total delivery capacity and throughput among the top PacBio service providers nationwide[22](index=22&type=chunk) - The research services segment added nearly **100** new partner hospitals and enterprises in H1, achieving total revenue of nearly **RMB 20 million**[22](index=22&type=chunk) - Preliminary completion of overseas laboratory construction in New Zealand, and domestically, independently developed and

人民财讯9月11日电，康圣环球(09960.HK)消息，公司旗下武汉希诺医学检验实验室通过CAP(美国病理 学家协会)认证。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康聖環球基因技術有限公司 呈交日期: 2025年9月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09960 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | USD | | 0.00025 | USD | | 500,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 2,000,000,000 | USD | | 0.00025 | USD | | 500,000 | 本月底法定/註冊 ...

Core Viewpoint - 康圣环球 (09960.HK) reported a decline in revenue and profit for the six months ending June 30, 2025, indicating challenges in its operational performance [1] Financial Performance - Revenue for the period was RMB 457 million, a decrease of 3.5% year-on-year [1] - Gross profit amounted to RMB 197 million, reflecting a year-on-year decline of 13.0% [1] - The loss attributable to the company's owners was RMB 36.07 million, compared to a profit of RMB 11.89 million in the same period last year [1] Margin Analysis - The gross margin decreased from 47.7% in the same period of 2024 to 43.0%, a drop of 4.7 percentage points [1] - The decline in gross margin was attributed to reduced revenue and increased fixed operating costs from new laboratories [1]

Major Events - Sihuan Pharmaceutical Holdings Group Ltd. successfully administered the first human dose of the new radiopharmaceutical conjugate drug 3D1015 [1] - Shenzhen International's joint venture Shenzhen Airlines plans to raise a total of 16 billion yuan in a phased capital increase [1] - Kangzheng Pharmaceutical received clinical trial approval for its innovative oral small molecule JAK1 inhibitor Povorcitinib for indications of vitiligo and suppurative hidradenitis [1] - Ruihe Digital signed a framework agreement with Tielin Superlight Technology to jointly advance the business of real-world asset tokenization [1] - Zhongxu Future will operate and launch a new mobile game "Miracle MU" titled "New Moon Continent" [1] Financial Performance - Noah Holdings reported a net profit attributable to shareholders of 179 million yuan for Q2, a year-on-year increase of 79% driven by strong growth in investment product distribution [1] - Trip.com Group reported a net profit of 4.846 billion yuan for Q2, an increase of 26.43% year-on-year [1] - Shijiazhuang Pharmaceutical Group announced a mid-year profit attributable to equity holders of approximately 283.5 million HKD, a year-on-year decrease of about 58.7% [1] - Zhongsheng Holdings reported a mid-year profit attributable to shareholders of 1.011 billion yuan, a decrease of 36% year-on-year [1] - SF Express City reported an adjusted net profit of approximately 160 million yuan, a year-on-year increase of 139% [1] - Baidu's subsidiary reported a mid-year profit attributable to shareholders of 47.999 million yuan, returning to profitability [1] - Li Auto reported a net profit of 1.093 billion yuan for Q2, a decrease of 0.91% year-on-year [1] - Shanghai Industrial Holdings reported a mid-year profit attributable to shareholders of 1.042 billion HKD, with an interim dividend of 0.42 HKD per share [1] - Beijing Holdings reported a mid-year profit attributable to shareholders of 3.404 billion yuan, an increase of 8.07% year-on-year [1] - Qingdao Port reported a net profit of 2.842 billion yuan, a year-on-year increase of 7.58% [1] - New China Life Insurance reported a net profit of 14.799 billion yuan, a year-on-year increase of 33.5% [1] - China Galaxy Securities reported a net profit of 6.488 billion yuan, a year-on-year increase of 47.86% [1] - China Taiping reported a 12.2% increase in shareholder profit, with a nearly 23% high growth in life insurance new business value [1] - China Resources Gas reported a mid-year profit attributable to shareholders of 2.403 billion HKD, a year-on-year decrease of 30.5% [1] - SF Holding reported a net profit of 5.738 billion yuan, a year-on-year increase of 19.37%, with volume growth exceeding the overall express delivery industry [1] - SMIC reported a net profit of approximately 320 million USD, a year-on-year increase of 35.6% [1] - SenseTime reported a revenue growth of 35.6% year-on-year, reaching 2.358 billion yuan [1] - BeiGene reported a net profit of 95.59 million USD, returning to profitability [1] - Fubo Group reported a mid-year net profit exceeding 100 million, driven by AI [1] - CITIC Securities reported a net profit of 13.719 billion yuan, a year-on-year increase of 29.79% [1] - Huadian International Power reported a net profit of 3.904 billion yuan, a year-on-year increase of 13.15% [1] Additional Financial Performance - Zhou Hei Ya reported a mid-year profit attributable to shareholders of 108 million yuan, a year-on-year increase of 228% [2] - Haitian Flavoring reported a net profit of 3.91 billion yuan, a year-on-year increase of 13.3% [2] - Dasheng Holdings reported a mid-year adjusted net profit growth of 79.6% driven by store expansion and membership growth [2] - CITIC Securities reported a net profit of 4.509 billion yuan, a year-on-year increase of 57.77% [2] - Huitongda reported a mid-year profit attributable to shareholders of 13.9 million yuan, a year-on-year increase of 10.81% [2] - Yunfeng Financial reported a mid-year profit attributable to shareholders of 486 million HKD, a year-on-year increase of 142.04% [2] - Jiufang Zhitu reported a mid-year profit attributable to shareholders of 865 million yuan, returning to profitability [2] - Air China reported a net loss of approximately 1.806 billion yuan, a year-on-year narrowing of 35.11% [2] - ZTE reported a net profit of approximately 5.058 billion yuan, a year-on-year decrease of 11.77% [2] - China Merchants Securities reported a net profit of 5.186 billion yuan, a year-on-year increase of 9.23% [2] - Datang Power reported a net profit of approximately 4.874 billion yuan, a year-on-year increase of 50.3% [2] - China Pacific Insurance reported a net profit of 27.885 billion yuan, a year-on-year increase of 11% [2] - Beijing Capital International Airport reported a post-tax loss of 164 million yuan, a year-on-year narrowing of 56.48% [2] - Dongguan Rural Commercial Bank reported a mid-year net profit of 2.629 billion yuan [2] - Shenzhen Holdings reported a mid-year loss attributable to shareholders of 2.618 billion HKD, a year-on-year increase of 137.76% [2] - China Southern Airlines reported a net loss of 1.534 billion yuan, a year-on-year increase of 45.54% [2] - COSCO Shipping Holdings reported a profit attributable to shareholders of 17.528 billion yuan, a year-on-year increase of 3.9% [2] - Guofu Hydrogen Energy reported revenue of 10.9 million yuan, actively expanding overseas cooperation and business layout [2] - Kangsheng Global reported a mid-year gross profit of 197 million yuan, with stable progress across all businesses [2] - Dongfang Electric reported a net profit of 1.91 billion yuan, a year-on-year increase of 12.91%, maintaining the industry's leading market share in nuclear and gas power [2] - Eagle Eye Technology reported a profit of 443,000 yuan, returning to profitability [2] - Haier Smart Home reported a profit attributable to shareholders of 12.033 billion yuan, a year-on-year increase of 15.6% [2] - EDA Group Holdings reached a partnership agreement with UTCPAY to collaborate in digital asset trading, Web3 technology, and blockchain applications [2] - Gilead Sciences reported that ASC30 oral tablets showed good and differentiated pharmacokinetic characteristics in the U.S. Phase Ib multi-dose escalation study [2]

Group 1 - The company reported a revenue of 457 million RMB and a gross profit of 197 million RMB for the six months ending June 30, 2025, with R&D costs amounting to 46.046 million RMB [1] - The hematology testing services saw a steady growth in hospital partnerships, adding over 90 new hospital clients in the first half of 2025, with the pediatric hematology segment adding 48 new cooperative hospitals [1] - The NGS testing IG/TCR rearrangement technology product sales increased by over 50%, showcasing the company's core technological advantages and product features [1] Group 2 - The company emphasized innovation-driven development, with 33 research articles published and 67 patents applied for in the first half of 2025, of which 29 were granted [2] - A total of 56 new R&D testing projects were added during the reporting period, including 16 related to molecular biology testing technology and 16 related to flow cytometry testing technology [2] - The core product in the immune repertoire, used for minimal residual disease detection in hematological malignancies, expanded its coverage to over 160 institutions across 26 provinces, with revenue growth of nearly 30% compared to the same period in 2024 [2]

Core Insights - The company reported a revenue of 457 million RMB and a gross profit of 197 million RMB for the six months ending June 30, 2025, with R&D costs amounting to 46.046 million RMB [1] - The hematology testing services saw a steady growth in hospital partnerships, adding over 90 new hospital clients in the first half of 2025 [1] - The pediatric hematology segment continued to expand, with 48 new hospital collaborations established during the same period [1] - The NGS testing product for IG/TCR rearrangement technology experienced over 50% sales growth, highlighting the company's core technological advantages [1] - In the neurology sector, the company expanded its testing projects, adding 34 new tests and 44 new collaborating hospitals [1] Innovation and R&D - The company emphasized innovation-driven development, publishing 33 research articles and applying for 67 patents, with 29 granted and 24 copyrights obtained in the first half of 2025 [2] - A total of 56 new R&D testing projects were introduced, including 16 related to molecular biology, 16 to flow cytometry, 7 to cytogenetics, and 6 to pathology [2] - The core product in the immune repertoire, used for minimal residual disease detection in hematological malignancies, expanded to over 160 institutions across 26 provinces, with revenue growth of nearly 30% compared to the same period in 2024 [2] - The company's subsidiary, Kangsheng Beitai, achieved a perfect score in the EuroClonality EQA program, marking a significant step towards internationalization in the field of immune repertoire testing in China [2]